Hongsheng Su

Title: The Innovations of Hongsheng Su

Introduction

Hongsheng Su is a notable inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of coagulation factor VIII fusion proteins. His work has implications for treating hemophilia and improving patient outcomes.

Latest Patents

Hongsheng Su holds a patent for an FVIII fusion protein and its use. This invention discloses a coagulation factor VIII fusion protein that is conjugated with polyalkylene glycol, resulting in an extended cyclic half-life. The active moiety of the coagulation factor VIII is either directly or indirectly linked by a peptide linker to a fusion partner. The fusion protein is further conjugated to polyalkylene glycol, significantly increasing its half-life compared to FVIII fusion proteins modified without polyalkylene glycol. This innovation represents a crucial advancement in the treatment of blood coagulation disorders.

Career Highlights

Hongsheng Su is currently employed at Zhengzhou Gensciences Inc., where he continues to work on innovative solutions in biotechnology. His expertise in protein engineering and drug development has positioned him as a key figure in his field.

Collaborations

He collaborates with talented individuals such as Xiaoshan Wang and Yu Wang, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Hongsheng Su's contributions to the field of biotechnology, particularly through his patented FVIII fusion protein, highlight his role as an influential inventor. His work not only advances scientific knowledge but also has the potential to improve the lives of patients with hemophilia.